Implicit price concessions to self-pay patients versus bad debt classification

This is one of the most frequently misapplied judgments in healthcare revenue recognition: booking the full self-pay rate and later expensing a large bad debt charge overstates both revenue and receivables during the billing period and manufactures a misleading spike in credit-loss expense later, when the shortfall was predictable all along from the entity's own collection history.

Does historical collection experience for a class of self-pay patients show a consistent, predictable pattern of not collecting the full billed amount, indicating an implicit price concession rather than a credit event? Has the entity effectively established a customary business practice of accepting less than the standard rate from certain patient segments, even without a formal discount policy? Is the shortfall predictable at the time of billing, or does it only emerge later from a patient-specific deterioration in creditworthiness that should instead be treated as an IFRS 9 credit loss?

1) Analyze historical net collection rates by self-pay/uninsured patient segment over a representative period (at least 2-3 years). 2) Determine whether the shortfall pattern is predictable at the time of billing (an implicit price concession) or only emerges from subsequent, patient-specific creditworthiness deterioration (a genuine credit event). 3) Where a consistent pattern of not collecting the full billed rate exists for a segment, reduce the transaction price (and hence recognized revenue) at the point of service to the amount the entity expects to actually collect for that segment. 4) Recognize an IFRS 9 expected credit loss allowance only for the residual credit risk on the resulting (lower) contractual receivable, do not also apply a full-rate ECL calculation on top of the price concession. 5) Apply the price-concession estimate consistently across all patients in the same segment, not selectively. 6) Periodically validate the price-concession rate against actual collections and adjust prospectively (with any change also flowing through revenue, not bad debt expense).

Estimate the implicit price concession using a portfolio approach based on historical net collection rates by patient/payor segment, refreshed at least annually; distinguish this estimate methodologically from the ECL allowance, which should address only incremental credit deterioration risk after the concession-adjusted price is established; apply the concession consistently to all patients within the same segment rather than case-by-case unless individual circumstances are genuinely distinguishable and documented.

Disclose the policy for identifying and measuring implicit price concessions separately from bad debt/ECL expense; present the price concession impact within revenue (as a transaction price reduction), not within operating expenses; disclose the ECL allowance methodology applied only to the concession-adjusted receivable; disclose segment-level collection analytics or historical net collection rates supporting the concession estimate where material.

• Recording the full standard rate as revenue and then recognizing a large bad debt expense for self-pay shortfalls that were, in substance, predictable at billing (an implicit price concession, not a credit loss)
• applying a single blended allowance rate without separating the price concession component from genuine post-billing credit risk, effectively double-counting the same economic shortfall
• inconsistent treatment across similar patient segments, applying concessions to some and full-rate-plus-ECL to others without a principled basis
• failing to update the concession rate as actual collection experience shifts.